AnaptysBio Inc (NASDAQ:ANAB) – Investment analysts at Jefferies Group issued their FY2022 earnings per share estimates for shares of AnaptysBio in a research report issued to clients and investors on Monday. Jefferies Group analyst B. Amin forecasts that the biotechnology company will post earnings per share of ($0.80) for the year. Jefferies Group has a “Buy” rating and a $145.00 price target on the stock.
Several other research firms have also commented on ANAB. Wedbush reaffirmed an “outperform” rating and set a $142.00 target price on shares of AnaptysBio in a report on Tuesday. SunTrust Banks upped their target price on AnaptysBio from $115.00 to $162.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Credit Suisse Group set a $135.00 target price on AnaptysBio and gave the company an “outperform” rating in a report on Tuesday, January 23rd. Robert W. Baird reaffirmed a “buy” rating and set a $144.00 target price (up from $81.00) on shares of AnaptysBio in a report on Friday, January 19th. Finally, ValuEngine raised AnaptysBio from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $118.67.
Shares of AnaptysBio (NASDAQ:ANAB) traded down $5.42 during midday trading on Wednesday, reaching $121.03. The company’s stock had a trading volume of 223,300 shares, compared to its average volume of 304,471. AnaptysBio has a 12-month low of $18.15 and a 12-month high of $134.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
Several large investors have recently bought and sold shares of ANAB. OppenheimerFunds Inc. bought a new position in shares of AnaptysBio during the fourth quarter valued at approximately $106,701,000. BlackRock Inc. grew its holdings in AnaptysBio by 104.1% in the 4th quarter. BlackRock Inc. now owns 1,393,305 shares of the biotechnology company’s stock worth $140,334,000 after buying an additional 710,574 shares in the last quarter. Citadel Advisors LLC bought a new position in AnaptysBio in the 3rd quarter worth approximately $20,406,000. Farallon Capital Management LLC grew its holdings in AnaptysBio by 128.0% in the 4th quarter. Farallon Capital Management LLC now owns 561,000 shares of the biotechnology company’s stock worth $56,504,000 after buying an additional 315,000 shares in the last quarter. Finally, Redmile Group LLC bought a new position in AnaptysBio in the 4th quarter worth approximately $23,150,000. 95.56% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “AnaptysBio Inc Forecasted to Post FY2022 Earnings of ($0.80) Per Share (ANAB)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/21/anaptysbio-inc-forecasted-to-post-fy2022-earnings-of-0-80-per-share-anab.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.